Psychiatry Boot Camp Titelbild

Psychiatry Boot Camp

Psychiatry Boot Camp

Von: Mark Mullen MD
Jetzt kostenlos hören, ohne Abo

Das größte Angebot der Saison | 0,99 € pro Monat für die ersten 3 Monate + 15 € Audible-Guthaben

Danach 6,99 €/Monat. Bedingungen gelten. Monatlich kündbar.
Über diesen Titel
 Your clear, practical introduction to the field of psychiatry. Each episode features a leading expert unpacking complex topics like suicide risk, schizophrenia, catatonia, and childhood anxiety. Originally created as a crash course for new doctors, Psychiatry Boot Camp has grown into essential listening for professionals preparing for residency, advancing their careers, or sharpening their clinical decision-making. Hosted by psychiatrist and educator Dr. Mark Mullen, the program delivers expert insight and practical teaching opportunities. Thanks to the participation of our incredible audience, the PBC team is proud to provide a trusted resource for students, clinicians, and anyone seeking a deeper understanding of psychiatry in practice. To Learn More Visit www.psychiatrybootcamp.com Got a Question? Email mark@psychiatrybootcamp.com© 2026 PBC Industries, LLC. All rights reserved. Bildung Erfolg im Beruf Hygiene & gesundes Leben Ökonomie
Folgen
  • Biting Back at Ticks and Christina Applegate’s Mystery Illness | Medlines Bonus Episode

    Biting Back at Ticks and Christina Applegate’s Mystery Illness | Medlines Bonus Episode
    Nov 9 2026
    In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover full phase three results for a Lyme disease vaccine, and Psychiatry Boot Camp host Dr. Mark Mullen pays a visit. They break down a new once monthly olanzapine shot for schizophrenia. Plus: a dementia study built on a 1972 British school reform, why Christina Applegate says her MS diagnosis was wrong, and GLP-1 drugs may affect drinking habits in the UK. Thank you to the Medlines team for the collab! Catch new episodes every Friday on YouTube and all your favorite podcast apps. To learn more, visit www.medlinespod.com Learn more about your ad choices. Visit megaphone.fm/adchoices
    Mehr anzeigen Weniger anzeigen
    16 Min.
  • Electroconvulsive Therapy (ECT): Mechanism, Efficacy, and Future Directions with Dr. Holly Lisanby

    Electroconvulsive Therapy (ECT): Mechanism, Efficacy, and Future Directions with Dr. Holly Lisanby
    Nov 2 2026
    In this episode of Psychiatry Boot Camp, Dr. Mark Mullen welcomes Dr. Holly Lisanby for a comprehensive, evidence-based review of electroconvulsive therapy (ECT). Dr. Lisanby traces the mechanism of action from its historical roots in chemically induced convulsive therapy through modern neuroimaging findings, covering the roles of neurotransmitter release, functional connectivity change, anticonvulsant properties, and neuroplasticity, before explaining why the rapidity of ECT's antidepressant response makes neurogenesis an unlikely primary driver. She also introduces the research program she founded developing magnetic seizure therapy (MST), describes the CREST trial demonstrating non-inferior efficacy to right unilateral ECT with significantly less memory loss, and explains why this finding points to the seizure as the primary therapeutic mechanism.The conversation moves systematically through the full clinical picture and Dr. Mullen and Dr. Lisanby share personal accounts of lives transformed by ECT framing the episode as both a clinical primer and an argument for why no psychiatrist should practice without access to this treatment.Takeaways: ECT has an exceptionally broad therapeutic spectrum and is among the most rapidly acting anti-suicidal interventions in psychiatry. Acute ECT courses should be dosed to wellness using measurement-based care with standardized rating scales rather than a fixed number of treatments; stopping too early after initial improvement substantially increases relapse risk. Cognitive side effects are meaningfully modifiable: right unilateral electrode placement combined with ultrabrief pulse width produces the least memory impairment without sacrificing efficacy, and switching from unilateral to bilateral should be considered after six treatments without response. After an acute ECT course, relapse rates without maintenance treatment approach 75%; the PRIDE trial demonstrated that combination pharmacotherapy (venlafaxine plus lithium) with symptom-titrated algorithm-based maintenance ECT (the STABLE protocol) sustains remission more effectively than medications alone. The CREST trial established that magnetic seizure therapy is non-inferior to right unilateral ECT in antidepressant efficacy with significantly less memory loss, providing the strongest evidence to date that the therapeutic mechanism is the seizure itself, not the applied electric field. References: Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study Electric field strength and focality in electroconvulsive therapy and magnetic seizure therapy: a finite element simulation study Magnetic seizure therapy of major depression Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST-MST): a randomised, double-blind, non-inferiority trial in Canada and the USA Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates Relief of expressed suicidal intent by ECT: a consortium for research in ECT study ECT in bipolar and unipolar depression: differences in speed of response ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial Antidepressant and cognitive effects of twice- versus three-times-weekly ECT Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial A Novel Strategy for Continuation ECT in Geriatric Depression: Phase 2 of the PRIDE Study Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy Chapter: 00:00 ECT Overview00:19 Meet Dr Lisanby01:22 ECT Works Fast03:02 Lives Saved Stories06:14 Training Access Matters07:03 How ECT Works10:16 Magnetic Seizure Therapy12:46 MST Evidence Trials14:25 Neuroplasticity BDNF16:56 What ECT Looks Like20:11 Who ECT Helps25:28 How Effective Is ECT27:54 Maintenance Strategy37:35 Safety Side Effects43:45 Stigma And Next Steps Learn more about your ad choices. Visit megaphone.fm/adchoices
    Mehr anzeigen Weniger anzeigen
    50 Min.
  • Will AI Replace Your Doctor? Replicants and "Robo-proxies" with Dr. Jacob Appel

    Will AI Replace Your Doctor? Replicants and "Robo-proxies" with Dr. Jacob Appel
    Oct 19 2026
    In this episode of Psychiatry Boot Camp, Dr. Mark Mullen continues his conversation with Dr. Jacob Appel, covering two intersecting frontiers. The replacement of human physicians by AI "replicants" and the emerging use of AI as a surrogate decision-maker, or "robo-proxy," for patients who lack decisional capacity. Dr. Appel argues that while AI will outperform human physicians in probabilistic, pattern-recognition tasks, it is structurally incapable of providing the authentic empathy, shared vulnerability, common sense, and irrational human trust that constitute the actual substance of healing and that deploying replicant physicians at scale will produce a deeply inequitable two-tiered healthcare system where wealthy patients see humans and less wealthy patients see machines. The second half of the episode addresses the coming reality of AI robo-proxies where patients appoint chatbots as their legal healthcare proxy to make decisions in the event of incapacity. Dr. Appel outlines four models by which this might occur, then catalogs the serious structural problems each presents. His closing advice is disarmingly simple. Write your advance directive the old-fashioned way, on paper, and tell someone you love what you want. Takeaways: AI performs well at tasks requiring 90–95% accuracy but medicine often demands near-certainty, and the "negative outcome penalty paradox" means physicians face increased liability whether they follow AI recommendations that turn out to be wrong or override them when the AI turns out to be right. Authentic emotional support, not simulated empathy, is a core component of healing. The deployment of replicant physicians at scale will create a two-tiered system in which those who can afford to will see human doctors while the majority of patients will be increasingly funneled toward AI-driven care. AI "robo-proxies" present profound legal and ethical problems as surrogate decision-makers. Until legal frameworks are built around robo-proxies, physicians who follow a robo-proxy's instructions over a family's objection face serious liability exposure regardless of whether the law ultimately supports the decision. SUPPORT OUR PARTNERS: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SimplePractice.com/bootcamp⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Now with AI documentation! Exclusive 7 day free trial and 50% off four months) Learn more and get transcripts for EVERY episode at https://www.psychiatrybootcamp.com/ For Sales Inquiries & Ad Rates, Please Contact:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sales@Human-Content.Com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Connect with HumanContent on Socials: @humancontentpods Produced by: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Human Content⁠ Chapter: 00:00 Meet Dr Jacob Appel00:29 Values Based Capacity Model02:15 Can Clinicians Make Time03:13 Will AI Replace Doctors06:47 Replicant Pros And Cons10:35 Empathy And Shared Vulnerability14:57 Trust Liability And Policy30:21 Robo Agents As Surrogates32:46 Robo Proxy Basics33:34 Can AI Improve Living Wills35:06 Why Choose a Robo Proxy36:38 Hallucinations and High Stakes38:06 Four Robo Proxy Models42:29 Bias and Family Fallout52:22 Legal Standards and Liability59:07 Activation Risks and Final Advice Learn more about your ad choices. Visit megaphone.fm/adchoices
    Mehr anzeigen Weniger anzeigen
    1 Std. und 5 Min.
adbl_web_anon_alc_button_suppression_t1
Noch keine Rezensionen vorhanden